A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects

Autor:	Salmaan Kanji, Isabelle Seguin, C. la Porte, M. Dennehy, Guijin Zhang, M. Ghannad, Elham Sabri, D. W. Cameron, Ranjeeta Mallick, D. Tardiff
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	0301 basic medicine RNA viruses Male Rifabutin Enzyme Metabolism Pharmacology Pathology and Laboratory Medicine Biochemistry Maraviroc chemistry.chemical_compound 0302 clinical medicine Drug Metabolism Immunodeficiency Viruses HIV Fusion Inhibitors Medicine and Health Sciences Medicine Drug Interactions Tissue Distribution 030212 general & internal medicine Enzyme Chemistry Multidisciplinary Pharmaceutics Area under the curve Middle Aged Healthy Volunteers Enzymes Anti-Bacterial Agents Medical Microbiology Viral Pathogens Viruses Female Pathogens medicine.drug Research Article Adult Adolescent Science 030106 microbiology Pain Drug-Drug Interactions Microbiology 03 medical and health sciences Cmin Young Adult Signs and Symptoms Pharmacokinetics Drug Therapy Diagnostic Medicine Retroviruses parasitic diseases Humans Microbial Pathogens Aged CYP3A4 business.industry Lentivirus Organisms Biology and Life Sciences HIV Proteins Myalgia Drug interaction Regimen chemistry Enzymology business
Zdroj:	PLoS ONE, Vol 14, Iss 10, p e0223969 (2019) PLoS ONE
ISSN:	1932-6203
Popis:	Effects of steady-state rifabutin on the pharmacokinetics of steady-state maraviroc were investigated in fourteen healthy adult female and male volunteers. Maraviroc 300 mg twice daily (BID) was given orally with food for fifteen days. On day six, rifabutin 300 mg once daily (QD, P.O.) was added to the regimen. Formal pharmacokinetic (PK) sampling was performed on days five and fifteen. Individual plasma drug concentration-time data for maraviroc, and rifabutin on day fifteen, were obtained using validated High Performance Liquid Chromatography (HPLC) tandem Mass Spectrometry (MS/MS). Rifabutin steady state exposure was comparable to data in the literature. Maraviroc area under the curve (AUC) and minimum plasma concentration (Clast or Cmin) were reduced by 17% and 30% respectively when co-administered with rifabutin. No unexpected or serious adverse eventsoccurred. Based on the reduced exposure of maraviroc observed in this study, increasing the dose of maraviroc may be studied to normalize its moderately reduced exposure following rifabutin co-administration, a moderate inducer of CYP3A4.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddea84e05cb923e8e5a567160e772789 https://doaj.org/article/007c10680b4842e7946c9380b2a5850c Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.